Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

(VIDEO) Rand Paul Catches Moderna CEO in Lie About Myocarditis, Exposes NIH Royalties


Moderna CEO Stéphane Bancel testified before Congress Wednesday on raising the price of the experimental COVID-19 shot.

However, the conversation didn’t stay on the cost of the mRNA gene therapy.

Senator Rand Paul (R-KY) pressed Bancel on the increased risk of myocarditis from the shot.

“Is there a higher incidence of myocarditis among adolescent males age 16 to 24 after taking your vaccine?” Paul asked.

“The data have shown actually…there’s less myocarditis for people who get the vaccine versus who gets COVID infection,” Bancel responded.

“That is not true!” Paul emphasized.

“I’d like to enter into the record six peer-reviewed papers…that say the complete opposite of what you say.”

“I also spoke with your president just last week and he readily acknowledged in private, that yes, there is an increased risk of myocarditis. The fact that you can’t say it in public is quite disturbing,” Paul explained.


Rand Paul also grilled Bancel on $400 million in royalties Moderna paid to the NIH.

“Do you believe it creates a conflict of interest for the government employees who are making money now off the vaccine to also be dictating the policy of how many times we have to take the vaccine?” Paul asked.

“Indeed, we recently made, before Christmas last year, a $400 million dollar payment to the NIH,” Bancel replied.


The New York Post reported on Moderna’s price hike of the COVID-19 jab that earns royalties for government employees.

Moderna CEO Stephane Bancel was called to testify after the company flagged plans to raise the vaccine’s price to as much as $130 per dose drew the ire of Democratic Senator Bernie Sanders, who chairs the influential Committee on Health, Education, Labor and Pensions and has long demanded lower drug prices.

Sanders on Wednesday asked Bancel to reconsider the price hikes, saying they could make it unaffordable for millions of Americans and were unjustified given the government’s research contributions and $1.7 billion in assistance in developing the vaccine. His comments echoed his January letter to Bancel.

Bancel said Moderna’s next COVID-19 shots will be more expensive because they will be sold in single-dose vials or pre-filled syringes for the commercial market versus the 10-dose vials it has sold to the government up until now.

The government in May plans to end the COVID public health emergency, putting much of the vaccine purchasing in the hands of the private sector.

As WeLoveTrump noted, Moderna reached a patent license agreement with the U.S. government over the experimental COVID-19 shot.

Moderna Announces COVID-19 Jab Patent License Agreement With U.S. Government

During an earnings call, CFO Jamey Mock said Moderna “entered into a nonexclusive patent license agreement with the National Institute of Allergy and Infectious Diseases, an institute or center of the NIH, to license certain patent rights concerning stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for the use in COVID-19 vaccine products or 2P technology.”

“Pursuant to the agreement, we have agreed to pay low single digit royalties on future net sales of our COVID-19 vaccines.”

“A key driver of the increase in cost of sales as a percent of product sales was a catch up royalty payment to the National Institutes of Health or NIH of $400 million, representing 8% of product sales in the fourth quarter,” Mock added.

Watch Bancel's full testimony:


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!